SCHEMBL23022183

SCHEMBL23022183

CN1CCC(n2cc(Oc3nc(Br)cnc3N)cn2)C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 3/20 0.36
FGFR1 P11362 4/20 0.36
FGFR2 P21802 4/20 0.36
FGFR3 P22607 4/20 0.36
EGFR P00533 2/20 0.36
BMPR1A P36894 1/20 0.35
ACVRL1 P37023 1/20 0.35
ACVR1 Q04771 1/20 0.35
IKBKE Q14164 1/20 0.34
TBK1 Q9UHD2 1/20 0.34
TLR7 Q9NYK1 1/20 0.33
NTRK1 P04629 1/20 0.33
ALOX15 P16050 1/20 0.32
AURKA O14965 1/20 0.32
AURKB Q96GD4 1/20 0.32
KDM4C Q9H3R0 2/20 0.31
KDM4E B2RXH2 1/20 0.31
KDM4A O75164 1/20 0.31
KDM5C P41229 1/20 0.31
KDM4D Q6B0I6 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23022232 0.93 MET (0.41) METFGFR1FGFR2FGFR3EGFR
SCHEMBL29507216 0.85 FGFR1 (0.36) METFGFR1FGFR2FGFR3EGFR
SCHEMBL29548382 0.84 KDM4C (0.34) METFGFR1FGFR2FGFR3EGFR
SCHEMBL24270016 0.84 KDM4C (0.34) METFGFR1FGFR2FGFR3EGFR
SCHEMBL29548344 0.83 MAP3K12 (0.34) FGFR1FGFR2FGFR3AURKAAURKB
SCHEMBL26686074 0.83 MAP3K12 (0.34) FGFR1FGFR2FGFR3AURKAAURKB
SCHEMBL26686079 0.83 MAP3K12 (0.34) FGFR1FGFR2FGFR3AURKAAURKB
SCHEMBL23022290 0.81 JAK1 (0.35) METAURKAAURKBKDM4CKDM4E
SCHEMBL23022319 0.81 FGFR1 (0.30) FGFR1FGFR2FGFR3KDM4CKDM4E
SCHEMBL23022209 0.81 LRRK2 (0.38) METIKBKETBK1AURKBKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114341127-B Aminopyrazine compounds as HPK1 inhibitors and uses thereof 百济神州有限公司 2024-12-17 CN disclosed
US-20220289712-A1 AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF BEONE MEDICINES I GMBH (CH) 2022-09-15 US disclosed
CN-114341127-A Aminopyrazine compounds as HPK1 inhibitors and uses thereof 百济神州有限公司 2022-04-12 CN disclosed
WO-2021032148-A1 AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF BEIGENE, LTD. (KY) 2021-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220289712-A1 AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF MAPKAPK5, STK25, STK35 MET 2240/4885FGFR1 2808/4885FGFR2 4003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.